Background: Systemic chemotherapy for advanced disease is another therapeutic option in
the management of metastases in soft tissue sarcoma (STS). Doxorubicin either alone or in …

Abstract Trabectedin (ET743, Yondelis®, manufactured by Baxter Oncology GmbH,
Halle/Westfalen, Germany, for Janssen Products, LP, Horsham, PA), derived from the marine …

Purpose The purpose of this retrospective analysis was to assess efficacy and tolerability of
trabectedin in soft tissue sarcoma (STS) in the routine clinical setting. Patients and methods …

Soft tissue sarcomas (STSs) are a heterogeneous group of solid tumors generally
associated with a poor prognosis. Even with optimal treatment for localized disease …

Introduction: Trabectedin, a marine-derived DNA-binding antineoplastic agent, has been
registered by the EMA and recently also by the FDA for the treatment of patients with …

Soft tissue sarcomas (STS) represent a variety of tumors of mesenchymal origin, accounting
for about 1% of all adult cancers. This group of tumors comprises over 60 different histotypes …

Purpose To evaluate whether trabectedin as first-line chemotherapy for advanced/metastatic
soft tissue sarcoma prolongs progression-free survival (PFS), compared to doxorubicin and …

Compared with conventional chemotherapy for advanced soft tissue sarcoma, trabectedin
has several distinguishing characteristics which, when optimized, may maximize clinical …

Introduction: Trabectedin gained the approval by the European Medicines Agency (EMA) in
2007 for the treatment of patients affected by soft-tissue sarcomas (STS). Its safety and …

Introduction The efficacy and tolerability of trabectedin in patients with soft tissue sarcoma
(STS) have been confirmed by various clinical studies involving lipo-and leiomyosarcomas …